Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05455606 · ClinicalTrials.gov registry record · NA
Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment
A NA study of Advanced Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm, sponsored by SWOG Cancer Research Network.
- Active
- Registry status
- NA
- Development phase
- 1,284
- Enrollment target
- 20
- Study locations
NCT05455606 is a NA study of Advanced Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm that is active but no longer recruiting, run by SWOG Cancer Research Network. The registered enrollment target is 1,284 participants, above the 165-participant average among 108 other Advanced Malignant Solid Neoplasm trials with a reported enrollment target (678% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT05455606, a NA study of Advanced Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm, is active but no longer recruiting, sponsored by SWOG Cancer Research Network.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,284 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial studies how well an educationally enhanced genomic tumor board (EGTB) intervention works to increase the number of patients with solid tumors that have come back (recurrent), do not respond to treatment (refractory), have spread to other parts of the body (metastatic), or are newly diagnosed and spread to other parts of the body (advanced) who receive genome-informed treatment. Genome-informed treatment refers to treatment based on the information found in genomic tumor test results. This study compares the usual approach to reviewing genomic tumor test results with the approach of having a genomic tumor board (GTB) review the test results. A GTB is team of doctors and scientists that have experience in understanding genomic changes and review genomic tumor test results. The tumor board helps to suggest whether there are other cancer treatment options based on patient genetic test results. The usual approach is to review genomic tumor test results without the GTB being involved. This study may help researchers learn if using a GTB enhances the treatment decision making process within 6 months of joining the study. This study may also help researchers learn if using the GTB increases doctors' understanding of genomic tumor test results and increases doctors' comfort level with genomic tumor tests.
Conditions Studied
Interventions
- OTHER Best Practice
- OTHER Educational Intervention
- OTHER Interview
- PROCEDURE Genomic Profile
- OTHER Chart Abstraction
Study Locations (20)
Illinois
- Illinois CancerCare-Bloomington - Bloomington
- Illinois CancerCare-Canton - Canton
- Carle at The Riverfront - Danville
- Illinois CancerCare-Galesburg - Galesburg
- Carle Physician Group-Mattoon/Charleston - Mattoon
- Illinois CancerCare-Ottawa Clinic - Ottawa
- Illinois CancerCare-Peoria - Peoria
- Carle Cancer Center - Urbana
Hawaii
- Hawaii Cancer Care Inc - Waterfront Plaza - Honolulu
- Queen's Medical Center - Honolulu
- Straub Clinic and Hospital - Honolulu
- University of Hawaii Cancer Center - Honolulu
- Kapiolani Medical Center for Women and Children - Honolulu
- Hawaii Cancer Care - Westridge - ‘Aiea
- Pali Momi Medical Center - ‘Aiea
Iowa
- Iowa Methodist Medical Center - Des Moines
- Medical Oncology and Hematology Associates-Des Moines - Des Moines
Arizona
- Cancer Center at Saint Joseph's - Phoenix
Georgia
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler - Savannah
Idaho
- Kootenai Clinic Cancer Services - Post Falls - Post Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,284 participants |
| Start Date | 2022-10-14 |
| Est. Completion | 2027-03-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05455606
The ClinicalTrials.gov registry entry for NCT05455606 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 1,284 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 165-participant average among 108 other Advanced Malignant Solid Neoplasm trials with a reported enrollment target (678% higher). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Advanced Malignant Solid Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Best Practice is the first listed.
NCT05455606 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Illinois, Hawaii, Iowa.
Frequently Asked Questions
What is clinical trial NCT05455606 about?
NCT05455606 is a clinical study titled "Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment". This clinical trial studies how well an educationally enhanced genomic tumor board (EGTB) intervention works to increase the number of patients with solid tumors that have come back (recurrent), do not respond to treatment (refractory), have spread to other parts of the body (metastatic), or are new...
What is the current status of trial NCT05455606?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,284 participants. The study started on 2022-10-14. Estimated completion is 2027-03-01.
What conditions does trial NCT05455606 study?
This clinical trial studies the following conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm.
What interventions are being tested in trial NCT05455606?
The interventions under investigation include: Best Practice (OTHER), Educational Intervention (OTHER), Interview (OTHER), Genomic Profile (PROCEDURE), Chart Abstraction (OTHER).
Who is sponsoring clinical trial NCT05455606?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05455606 being conducted?
This trial has 20 study locations across Arizona, Georgia, Hawaii, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial
RECRUITING · NA
-
Educational Tools for the Improvement of Early Advance Care Planning in Adolescents and Young Adults With Advanced Solid Tumors and High-Grade Brain Tumors
RECRUITING · NA
-
Technology-Enhanced Palliative Care for Advanced Cancer Patients
ACTIVE NOT RECRUITING · NA
-
Mindfulness-Based Intervention for Latino Cancer Patients and Their Caregivers
ACTIVE NOT RECRUITING · NA
-
Learning Collaborative Versus Technical Assistance in Delivering a Palliative Care Program to Patients With Advanced Cancer and Their Caregivers
ACTIVE NOT RECRUITING · NA
-
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Advanced Malignant Solid Neoplasm
All registered trials for this condition
Metastatic Malignant Solid Neoplasm
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.